🔉 Did tinnitus loudness improve?
None shown.
No controlled evidence that sound therapy durably reduces the percept. Newer music-therapy meta-analyses report loudness improvements, but from low-quality trials.
Sound therapy & masking for Tinnitus: What Does the Evidence Show?
Sound Therapy
Current evidence
Widely used, low-risk, valued by many — but controlled trials have not established a benefit beyond comparison sounds or placebo effects.
Evidence strength: Limited (2/5) · Tier 4 — supportive/symptom-management (limited treatment-specific evidence) · Evidence independence: Primarily independent.
Background sound — noise, nature sounds, music, sound generators or apps — used to partially cover tinnitus, ease its intrusiveness, and help sleep and focus.
Did tinnitus loudness or distress improve?
🧠 Did tinnitus distress improve?
Limited.
Cochrane 2018: NO usable trial data exist for sound therapy vs waitlist/placebo/information — the central question has simply never been answered; the 8 trials (N=590) only compared device types, with no differences found. Guideline status: 'Option'. Many individuals still find it genuinely helpful day to day.
Loudness means the tinnitus percept itself became quieter (psychoacoustic matching or loudness ratings). Distress means questionnaire scores such as THI/TFI, sleep, anxiety or quality of life improved — the sound may be unchanged. A THI/TFI improvement is never evidence the tinnitus got quieter.
How strong is the evidence?
Score 2/5 CONFIRMED after formal re-evaluation of the MOST trial (N=440, the largest double-blind sound-therapy RCT, eClinicalMedicine 2025): all four active sound arms improved similarly; the customized (DFCRS) arm beat unmodified music by only ~4 THI points (statistically significant, clinically small, no multiplicity adjustment) and the trial has no no-sound arm, so placebo effects cannot be excluded — the authors say so themselves. This is consistent with Cochrane 2018 (no strong evidence) and the guideline split (AAO-HNSF: option; NICE/EU: research-only; German S3: against sound generators). A large trial does not raise a rating by size alone; what it shows is modest, possibly non-specific benefit.
What the studies found 6 tracked
Sound therapy (amplification devices and sound generators) for tinnitus (Cochrane Review)
Sereda M, et al. · Cochrane Database of Systematic Reviews · 2018 · N=590 (8 trials) · Systematic review of RCTs
Crucially: NO usable data existed for any of the three main comparisons (sound therapy vs waitlist, vs placebo, or vs education alone). The 8 trials only compared device types — hearing aids vs sound generators vs combination devices — with insufficient evidence of any difference (low/very-low certainty).
This is absence of evidence, not 'tested and found no better': trials answering the sound-therapy-vs-placebo question simply have not produced usable data. Sound remains widely used, low-risk, and valued by many patients.
TRTT: Tinnitus Retraining Therapy vs standard of care
Scherer RW, Formby C, et al. · JAMA Otolaryngology–Head & Neck Surgery · 2019 · N=151 · Multicenter placebo-controlled RCT (6 US military hospitals)
TRT was not superior to standard of care — all three arms improved substantially (within-group TQ effect sizes −1.32, −1.16, −1.01) with few between-group differences. 77.5% (86/111 with data) achieved ≥7-point TQ reduction at 18 months.
Follow-up analyses attribute most benefit to the counseling component, not the sound generators.
MOST trial: modified sound therapy, 4-arm double-blind RCT (DFCRS arm)
Tang D, Gu D, Gong J, et al. · eClinicalMedicine · 2025 · N=440 randomized (UM 111 / UM+NBN 110 / HFEM 108 / DFCRS 111), all ITT · 4-arm multicentre double-blind RCT (participants + clinicians blinded); daily 2-h listening for 9 months; NO no-treatment or sham arm — unmodified music (UM) is the reference
The largest double-blind sound-therapy RCT. Only 1 of 440 participants reached complete remission. All arms improved (overall THI median 50→35, p<0.0001 — within-group). Between arms (GEE vs unmodified music): the customized DFCRS arm was better by −4.37 THI points [95% CI −6.25, −2.48], p<0.0001 — statistically significant but SMALL; fixed high-frequency enhancement (HFEM) was WORSE than unmodified music (+2.11, p=0.039); narrowband-noise mixing added nothing (p=0.75).
VAS-loudness fell in ALL arms (DFCRS greater in the first 3 months); the design cannot separate sound-specific benefit from placebo/natural fluctuation — the authors say so explicitly. No multiplicity adjustment. No adverse events in any group. ChiCTR2000039007; Chinese public funding; no competing interests declared. Registered on ChiCTR — invisible to CTgov-only discovery (audit finding).
AAO-HNSF Clinical Practice Guideline: Tinnitus
Tunkel DE, Bauer CA, Sun GH, et al. · Otolaryngology–Head and Neck Surgery · 2014 · N=Guideline (23-author multidisciplinary panel) · Clinical practice guideline (US)
RECOMMENDS: hearing-aid evaluation (with hearing loss) and CBT for persistent bothersome tinnitus. OPTION: sound therapy ('may recommend'). AGAINST routine use: medical therapy (antidepressants, anticonvulsants, anxiolytics, intratympanic drugs), dietary supplements (Ginkgo, melatonin, zinc), and rTMS. NO RECOMMENDATION: acupuncture.
Guidelines are consensus documents, not new trial data. Where the three major guidelines disagree — chiefly on sound therapy (AAO-HNSF: option; NICE and the European guideline: research-only; the German S3 guideline: against sound generators) — this platform shows the disagreement rather than picking a side. Statement strengths read from the published abstracts; full-text verbatim wording not independently re-read.
NICE guideline NG155: Tinnitus — assessment and management
National Institute for Health and Care Excellence · NICE (UK) · 2020 · N=National guideline · Clinical practice guideline (UK)
Amplification: OFFER with hearing loss affecting communication; CONSIDER with hearing loss without communication difficulty; DO NOT OFFER without hearing loss. Psychological therapies (stepped): digital tinnitus-related CBT → group interventions (MBCT/ACT/CBT) → individual CBT. Betahistine: 'Do not offer betahistine to treat tinnitus.' Sound therapy and neuromodulation: 'We were unable to make recommendations for practice in this area.'
Also advises against psychoacoustic pitch/loudness matching for assessment. Read from the official NICE pathway document (NBK557037 mirror). NICE's sound-therapy position (no practice recommendation) conflicts with AAO-HNSF's 'option' — shown as a disagreement, not resolved by this platform.
European multidisciplinary guideline for tinnitus
Cima RFF, Mazurek B, Haider H, et al. · HNO · 2019 · N=Multinational guideline · Clinical practice guideline (Europe)
CBT: STRONG recommendation FOR. Hearing aids: FOR, with hearing loss. Sound therapy: recommendation for RESEARCH only (no practice recommendation — not an 'against'). Pharmacotherapy: weak recommendation AGAINST. Transcranial electrical stimulation: AGAINST.
Stances verified via a peer-reviewed secondary source (Langguth et al., J Clin Med 2023, PMC10178961) because the primary full text is paywalled; verbatim wording and grading system therefore marked unable-to-verify. Together with AAO-HNSF 2014 and NICE NG155, the three guidelines agree on CBT (for) and drugs (against) and diverge on sound therapy.
What are the limitations?
- The sound-therapy-vs-placebo question has never produced usable trial data (absence of evidence, not proof of no effect)
- Effects end when the sound stops
- Commercial products often oversell the science
Has the result been independently replicated?
Conflicting results. Results discordant across independent trials; Cochrane 2018 found no strong evidence. The MOST trial (N=440, double-blind, 2025) found all active sound arms improved similarly, with a small advantage for customized modulation and no placebo arm — formally reviewed 2026-09-04, rating unchanged.
What should patients know about safety?
Safety evidence: Strong. Very safe at comfortable volumes; keep sound below or at the tinnitus level rather than drowning it out.
Is it available?
Regulatory status: Guideline 'option'; some tinnitus maskers are FDA-cleared, other consumer sound products are not specifically authorized for tinnitus. AAO-HNSF 2014 lists sound therapy as an option (benefit/harm balance, medium-quality evidence).
Availability: Free apps to clinical sound generators · Europe: Same · Cost (approx.): Free–$500 (bedside/wearable generators)
Related clinical trials 1
Tracked trials are research in progress, not recommended treatments.
Related treatments 3
- Notched sound / notched music therapy — Music with your tinnitus frequency carved out — a modest, unconfirmed loudness effect in tonal tinnitus.
- Levo System (sleep-time sound matching) — FDA-cleared sound therapy played during sleep, matched to your tinnitus 'sound print' — one small positive…
- Neuromonics (and other discontinued cleared devices) — A once heavily marketed $5,000 'acoustic desensitization' program — FDA-cleared, weakly evidenced, now…
Claim checks that mention this treatment
From Tinnitus Claims: Fact vs. Evidence, which checks popular claims against the research. It does not change this treatment’s evidence rating.
Evidence last reviewed: 2026-09-04 · Evidence included through: 2026-09-04 · Confidence: high. Open the interactive evidence profile · How we rate evidence.
This page summarizes published research for education. It is not medical advice; it cannot say what will work for any individual. Discuss treatment decisions with a qualified clinician.